INVESTORS

Press Releases

Precision BioSciences Announces Change to its Board of Directors
November 10, 2022
- Raymond F. Schinazi , Ph.D., to Step Down from Board of Directors and Continue as a Member of the Company’s Scientific Advisory Board (SAB) DURHAM, N.C. --(BUSINESS WIRE)--Nov. 10, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex...
Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting
November 3, 2022
DURHAM, N.C. --(BUSINESS WIRE)--Nov. 3, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that an abstract on the effective cell dose and functional attributes...
Precision BioSciences Announces Senior Leadership Organizational Changes
September 2, 2022
DURHAM, N.C. --(BUSINESS WIRE)--Sep. 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced promotions and organizational changes that impact responsibilities...
Displaying 1 - 10 of 31

Investors

Investor Tools